Please use this identifier to cite or link to this item:
http://acervodigital.unesp.br/handle/11449/7692
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Baldan, Helen M. | - |
dc.contributor.author | De Rosa, Helene J. | - |
dc.contributor.author | Brunetti, Iguatemy Lourenço | - |
dc.contributor.author | Ximenes, Valdecir Farias | - |
dc.contributor.author | Machado, Rosangela G. P. | - |
dc.date.accessioned | 2014-05-20T13:24:37Z | - |
dc.date.accessioned | 2016-10-25T16:45:20Z | - |
dc.date.available | 2014-05-20T13:24:37Z | - |
dc.date.available | 2016-10-25T16:45:20Z | - |
dc.date.issued | 2007-11-01 | - |
dc.identifier | http://dx.doi.org/10.1002/bdd.570 | - |
dc.identifier.citation | Biopharmaceutics & Drug Disposition. Chichester: John Wiley & Sons Ltd, v. 28, n. 8, p. 409-413, 2007. | - |
dc.identifier.issn | 0142-2782 | - |
dc.identifier.uri | http://hdl.handle.net/11449/7692 | - |
dc.identifier.uri | http://acervodigital.unesp.br/handle/11449/7692 | - |
dc.description.abstract | Tuberculosis chemotherapy involves combination of the drugs isoniazid (INH), rifampicin (RMP) and pyrazinamide (PYR) for a 6-month period. The present work investigated the influence of RMP and PYR on the pharmacokinetic parameters of INH when groups of rats were pre-treated for 21 days with INH alone or in combination with RMP and/or PYR, in the following amounts per kg body weight: INH 100 mg; INH 100 mg + RMP 100 mg; INH 100 mg + PYR 350 mg; INH 100 mg + PYR 350 mg + RMP 100 mg. It was found that the co-administration of PYR caused an increase in the INH distribution volume (V-d/F), half-life of elimination t(1)/2(beta)) and clearance (Cl-T/F), and a decrease in the area under curve 0 to 24 h (AUC). Co-administration of RMP caused an increase in the Cl-T/F and a decrease in the AUC. The combination INH + PYR + RMP caused an increase in the Cl-T/F and a decrease in the AUC. These significant pharmacokinetic interactions between the tuberculostatic drugs might be related to differences in the therapeutic and toxic effects. Copyright 0( 2007 John Wiley & Sons, Ltd. | en |
dc.format.extent | 409-413 | - |
dc.language.iso | eng | - |
dc.publisher | Wiley-Blackwell | - |
dc.source | Web of Science | - |
dc.subject | pharmacokinetics | pt |
dc.subject | isoniazid | pt |
dc.subject | pyrazinamide | pt |
dc.subject | rifampicin | pt |
dc.title | The effect of rifampicin and pyrazinamide on isoniazid pharmacokinetics in rats | en |
dc.type | outro | - |
dc.contributor.institution | Universidade Estadual Paulista (UNESP) | - |
dc.description.affiliation | Univ Estadual Paulista, Fac Ciências Farmaceut, Dept Principios Ativos Nat, Araraquara, SP, Brazil | - |
dc.description.affiliation | Univ Estadual Paulista, Fac Ciências Farmaceut, Dept Analises Clinicas, Araraquara, SP, Brazil | - |
dc.description.affiliation | Univ Estadual Paulista, Fac Ciências, Dept Quim, Bauru, SP, Brazil | - |
dc.description.affiliationUnesp | Univ Estadual Paulista, Fac Ciências Farmaceut, Dept Principios Ativos Nat, Araraquara, SP, Brazil | - |
dc.description.affiliationUnesp | Univ Estadual Paulista, Fac Ciências Farmaceut, Dept Analises Clinicas, Araraquara, SP, Brazil | - |
dc.description.affiliationUnesp | Univ Estadual Paulista, Fac Ciências, Dept Quim, Bauru, SP, Brazil | - |
dc.identifier.doi | 10.1002/bdd.570 | - |
dc.identifier.wos | WOS:000251955200001 | - |
dc.rights.accessRights | Acesso restrito | - |
dc.relation.ispartof | Biopharmaceutics & Drug Disposition | - |
Appears in Collections: | Artigos, TCCs, Teses e Dissertações da Unesp |
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.